MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-12-2024
Psychemedics Corporation Gross Profit 2011-2025 | PMD
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Psychemedics Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.41 M | 9.29 M | 10.3 M | 4.89 M | 16.4 M | 20.6 M | 19.8 M | 21.4 M | 12.7 M | 15.1 M | 15.4 M | 14.3 M | 14.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.4 M | 4.89 M | 14.1 M |
Quarterly Gross Profit Psychemedics Corporation
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.04 M | 1.55 M | 2.12 M | - | 2.09 M | 2.06 M | 2.2 M | - | 2.33 M | 2.27 M | 2.44 M | - | 3.08 M | 2.44 M | 2.57 M | 1.28 M | 1.13 M | -252 K | 2.73 M | 3.48 M | 4.38 M | 4.17 M | 4.41 M | 4.73 M | 5.36 M | 5.17 M | 5.36 M | 4.78 M | 5.12 M | 4.61 M | 5.32 M | 6.4 M | 7.1 M | 5.21 M | 2.74 M | 2.65 M | 3.46 M | 3.27 M | 3.34 M | 3.48 M | 3.97 M | 3.89 M | 3.8 M | 3.65 M | 4.18 M | 4.08 M | 3.49 M | 2.77 M | 3.72 M | 4.1 M | 3.66 M | 3.17 M | 3.94 M | 3.74 M | 3.62 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.1 M | -252 K | 3.51 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
30.6 M | $ 18.98 | -0.32 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
364 M | $ 20.62 | 0.26 % | $ 222 M |  China |
 |
Co-Diagnostics
CODX
|
2.63 M | $ 0.18 | -21.16 % | $ 5.28 M | USA |
 |
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
53 M | $ 39.31 | 0.1 % | $ 1.09 B | USA |
 |
Danaher Corporation
DHR
|
14.2 B | $ 230.67 | 0.02 % | $ 169 B | USA |
 |
DarioHealth Corp.
DRIO
|
5.98 M | $ 10.7 | 2.0 % | $ 304 M | Israel |
 |
BioNano Genomics
BNGO
|
2.77 M | $ 1.5 | 0.67 % | $ 1.91 M | USA |
 |
Exact Sciences Corporation
EXAS
|
493 M | $ 101.9 | -0.03 % | $ 18.9 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M |  Britain |
 |
DexCom
DXCM
|
2.29 B | $ 67.06 | -0.61 % | $ 25.9 B | USA |
 |
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 26.49 | -0.41 % | $ 801 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
81.6 M | $ 19.07 | -0.68 % | $ 1.03 B | USA |
 |
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | USA |
 |
Anixa Biosciences
ANIX
|
83.8 K | $ 3.12 | -1.89 % | $ 99.5 K | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
3.79 B | $ 227.69 | 0.26 % | $ 41.3 B | USA |
 |
Guardant Health
GH
|
144 M | $ 100.6 | -0.78 % | $ 12.3 B | USA |
 |
Aspira Women's Health
AWH
|
4.32 M | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
585 M | $ 6.17 | -2.22 % | $ 559 M | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.76 | -1.24 % | $ 2.56 M | USA |
 |
Neogen Corporation
NEOG
|
421 M | $ 7.05 | -2.35 % | $ 1.53 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
7.77 B | $ 27.39 | 0.48 % | $ 20 B |  Niderland |
 |
Personalis
PSNL
|
22.1 M | $ 7.97 | 0.5 % | $ 472 M | USA |
 |
Quidel Corporation
QDEL
|
1.35 B | $ 29.3 | - | $ 1.23 B | USA |
 |
National Research Corporation
NRC
|
81.5 M | $ 18.65 | -1.69 % | $ 458 M | USA |
 |
RadNet
RDNT
|
154 M | $ 71.49 | -1.81 % | $ 5.22 B | USA |
 |
Illumina
ILMN
|
2.86 B | $ 132.75 | -1.29 % | $ 21.1 B | USA |
 |
Charles River Laboratories International
CRL
|
958 M | $ 201.98 | -0.58 % | $ 10.4 B | USA |
 |
Soleno Therapeutics
SLNO
|
-58.5 K | $ 46.29 | -2.65 % | $ 1.86 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 175.49 | -0.02 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
18.5 M | $ 6.72 | -2.04 % | $ 871 M | USA |
 |
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
3.62 B | $ 253.07 | 0.04 % | $ 21.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
817 M | $ 183.0 | 0.35 % | $ 15.1 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
2.38 B | $ 682.32 | -0.81 % | $ 56.3 B | USA |
 |
Lantheus Holdings
LNTH
|
988 M | $ 67.16 | -0.27 % | $ 4.65 B | USA |
 |
Mettler-Toledo International
MTD
|
2.33 B | $ 1 414.32 | -0.36 % | $ 30 B |  Schweiz |